Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Udine – page 14

251 clinical trials in Udine, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Udine at a glance
251
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

251 trials in Udine

Open in trial search

Oesophageal squamous cell carcinoma

Not recruiting

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

T-cell type acute leukaemia

Not recruiting

Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Plasma cell myeloma+1

Not recruiting

Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Fallopian tube cancer+2

Not recruiting

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Relacorilant
  • Sponsor:Corcept Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Udine

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials investigating treatments for various cancer types, including leukemia, gastric cancer, and multiple myeloma. Studies focus on targeted therapies and immunotherapy approaches.

  • Chronic Myeloid Leukemia Treatment
  • Gastroesophageal Cancer Therapy
  • Advanced Pancreatic Cancer Management

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Autoimmune Conditions

Studies examining new therapeutic options for inflammatory and autoimmune disorders, with particular focus on psoriatic arthritis and Sjögren's Syndrome.

  • Biomarker Analysis in Psoriatic Arthritis
  • Novel Treatments for Inflammatory Conditions
  • Long-term Disease Management

Trials aim to evaluate both safety and efficacy of innovative biological treatments.

03 Cardiovascular Studies

Research focusing on heart health and prevention, including studies of heart failure prevention and treatment of recurrent pericarditis.

  • Heart Failure Prevention Strategies
  • Pericarditis Treatment Innovation
  • Cardiovascular Risk Management

Investigations center on both preventive approaches and therapeutic interventions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.